Blood Plasma Derivatives Market 2023: COVID19 Outbreak Impact Analysis of Key Points Influencing the Growth of the Market
Key Highlights :
The blood plasma derivatives market is expected to reach US$ 51,119.24 million by 2028 from US$ 29.886.12 million in 2022; it is estimated to record a CAGR of 9.4% from 2022 to 2028. The global blood plasma derivatives market is being driven by the rising demand for blood plasma-derived products, the increasing prevalence of chronic diseases, and the growing awareness of the therapeutic benefits of blood plasma derivatives. Additionally, the increasing number of blood donation centers and the growing demand for blood plasma derivatives in the pharmaceutical and biotechnology industries are also expected to boost the growth of the blood plasma derivatives market.
The blood plasma derivatives market is segmented on the basis of product type, application, and region. By product type, the market is divided into albumin, immunoglobulin, clotting factors, and other blood plasma derivatives. Among these, the albumin segment is expected to have the largest market share during the forecast period. This is mainly attributed to the increasing demand for albumin in the treatment of various diseases, such as hypoproteinemia, burns, and liver cirrhosis.
By application, the market is segmented into therapeutic, research, and other applications. The therapeutic segment is expected to be the largest segment in the blood plasma derivatives market. This is mainly due to the increasing use of blood plasma derivatives in the treatment of various chronic diseases, such as hemophilia, hepatitis, and immune deficiency disorders.
Geographically, the global blood plasma derivatives market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the blood plasma derivatives market during the forecast period. This is mainly due to the presence of well-established healthcare infrastructure, the increasing prevalence of chronic diseases, and the growing awareness about the therapeutic benefits of blood plasma derivatives.
The key players operating in the blood plasma derivatives market are Grifols SA, SK Plasma Co Ltd, Octapharma AG, Monobind Inc, Intas Pharmaceuticals Ltd, Fusion Health Care Pvt Ltd, Takeda Pharmaceutical Co Ltd, CSL Behring LLC, LFB SA, and Kedrion SpA. These players are focusing on product development, collaborations, and mergers & acquisitions to expand their presence in the global blood plasma derivatives market.
The report includes comprehensive information about the market's major competitors, including various organizations, companies, associations, suppliers and manufacturers competing for production, supply, sales, revenue generation, and after-sales performance expectations. The bargaining power of numerous vendors and buyers have also been included in the research report.
The study of the Blood Plasma Derivatives report is done based on the significant research methodology that provides the analytical inspection of the global market based on various segments the Industry is alienated into also the summary and advance size of the marketplace owing to the various outlook possibilities. The report also gives 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the strength, weaknesses, opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses.
